All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1900+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Sanofi pays Nurix Therapeutics $15M upfront + $465M biobucks for exclusive rights to a “once-undruggable” transcription factor degrader targeting autoimmune diseases
Small molecule, protein degrader - Read more

Xcell Biosciences out-licenses AVATAR cell manufacturing tech to bluebird bio for Lyfgenia gene therapy supply in sickle cell disease
Gene therapy, gene therapy manufacturing, sickle cell disease, manufacturing platform - Read more

THE GOOD
Clinical Trials

Desentum touts positive Ph1 results for pollen allergy vaccine DM-101PX
Vaccine, allergic reaction, pollen allergy - Read more

BioMarin's Palynziq (targeting phenylalanine) enzymatic therapy delivers positive Ph3 data for adolescents with PKU
Recombinant enzyme, phenylketonuria - Read more

Medera's showcases promising Ph1/2a results for gene therapy SRD-002 (targeting SERCA2a) in heart failure with preserved ejection fraction
Gene therapy, heart failure, drug delivery, adeno-associated virus (AAV) - Read more

PRESENTED BY ALTITUDE MARKETING
If any of the biotechs featured in this newsletter are your potential customers, we’re the only marketing agency you need.

Sure, marketing is essential. But for scientific organizations, it’s also annoying.

It pulls you away from core product development, and you’re left onboarding junior-level resources or relying on your nephew’s buddy to run search ads.

Why not partner with a fully integrated agency that reaches and converts your hard-to-reach and harder-to-convert biotech prospects? It’s what we’ve done for 21 years with a team of 40 experts, all based an hour north of Philadelphia.

We’re world-class marketers who know science, so your world-class scientists don’t have to moonlight as mediocre marketers. Talk to us now.

✅ More Good News ✅

THE GOOD
Company Launches

Artis BioSolutions launches as cell and gene therapy CDMO via acquiring Landmark Bio
CDMO (Contract Development & Manufacturing Organization), cell therapy, cell therapy manufacturing, gene therapy, gene therapy manufacturing - Read more

THE GOOD
Fundraises

Atsena Therapeutics raises $150M Series C to advance gene therapy for rare genetic eye disease
Gene therapy, X-linked retinoschisis, adeno-associated virus (AAV) - Read more

CMR Surgical $200M financing, expanding US rollout of Versius surgical robot system
Medical device, robotics, surgical Robotics - Read more

THE GOOD
Investments

CellCentric opens Boston office as second hub for international operations
New facility, small molecule, multiple myeloma, cancer - Read more

THE GOOD
Mergers & Acquisitions

Concentra Biosciences to acquire Allakos for $0.33 per share in cash, expected to close in May 2025
Monoclonal antibody, inflammatory disease, cancer, solid tumor - Read more

Artis Biosolutions acquires Landmark Bio, jumping into the cell and gene therapy CDMO space
CDMO (Contract Development & Manufacturing Organization), cell therapy, cell therapy manufacturing, gene therapy, gene therapy manufacturing - Read more

Marubeni acquires 60% of Sumitomo Pharma's Asian operations for $300M, creating new pharmaceutical company with option for full ownership by 2029
M&A strategy, big pharma strategy - Read more

Siemens acquires Dotmatics for $5.1 billion, expanding its AI-powered software portfolio into Life Sciences R&D
Software, AI - Read more

Roche acquires Notch Therapeutics' Canadian division after layoffs and lab closures, integrating its preclinical cell therapy technology
Cell therapy, induced pluripotent stem cell (IPSC/iPS cell), stem cell-derived therapy, T cell therapy, allogeneic cell therapy, cancer, autoimmune disease - Read more

THE GOOD
Partnerships

Leica Biosystems, Bio-Techne, expanding partnership to automate RNAscope Multiomic LS Assay for spatial biology research
Spatial analysis, spatial biology, -omics, equipment/instrumentation - Read more

IgniteData, AstraZeneca, Memorial Sloan Kettering partner to deploy Archer EHR-to-EDC automation tool in Phase III trial
Electronic health records, clinical trial tech collab - Read more

Medtronic, Methinks AI partnership aims to enhance stroke care using AI radiological triage system alongside Medtronic's neurovascular treatments
AI, stroke - Read more

knownwell to be listed as a “primary care provider” on Eli Lilly LillyDirect DTC platform
Direct-to-consumer, metabolic disease, obesity, diabetes - Read more

R3 Distribution partners with Drug Intervention Institute to distribute ONEbox kits with naloxone and training videos for overdose emergencies
Supply contract, opioid epidemic, opioid overdose reversal - Read more

THE GOOD
Politics & Policy

Maryland judge requires federal agencies to reverse probationary worker terminations as states challenge controversial cuts
Research layoffs, Public agency layoffs, US Department of Health & Human Services (HHS) - Read more [Paywall]

THE GOOD
Product Launches

Amneal Pharmaceuticals launches Boruzu, a RTU bortezomib (targeting 26S proteasome) injection for cancer treatment, developed with Shilpa Medicare
Small molecule, multiple myeloma, lymphoma, drug formulation - Read more

THE GOOD
Research

Researchers develop proteomics-based patient models to personalize treatments for childhood cancer, complementing genomic approaches with protein analysis
Cancer, cancer detection/screening, proteomics - Read more

Personalized TIL immunotherapy combined with pembrolizumab (targeting PD-1) significantly reduced metastatic gastrointestinal tumors in clinical trial patients
Cell therapy, tumor-inflitrating lymphocyte (TIL), gastrointestinal cancer - Read more

THE GOOD
Strategic Plans

Danish biotech Pila Pharma seeks partnership or acquisition to advance obesity and diabetes drug XEN-D0501 (targeting TRPV1) to market
Small molecule, obesity, diabetes, partnership search - Read more

PRESENTED BY YOU?
Get the attention of 1900+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Adverse Events

Patient in Cabaletta Bio's autoimmune CAR-T trial experienced neurotoxicity (which resolved quickly after treatment)
Cell therapy, CAR-T, autoimmune disease - Read more

THE BAD
Clinical Trials

Edgewise Therapeutics' spooks investors with EDG-7500 (cardiac sarcomere modulator) Ph2 results in hypertrophic cardiomyopathy, as efficacy data overshadowed by serious atrial fibrillation events
Small molecule, hypertrophic cardiomyopathy - Read more

Roche's high-dose Ocrevus (targeting CD20) flops in Ph3 multiple sclerosis trial versus standard dose
Monoclonal antibody, multiple sclerosis (MS) - Read more

THE BAD
Earnings & Finances

Despite “a slight” predicted increase to Boehringer Ingelheim sales in 2025, US market uncertainties and health agency cuts could be cause for concern
Big pharma strategy, tariffs - Read more

THE BAD
Lawsuits

FTC pauses lawsuit against major PBMs due to commissioner shortage after leadership changes
Federal Trade Comission (FTC), pharmacy benefit managers - Read more

THE BAD
Layoffs

Gilead Sciences cutting 149 Bay Area jobs
Small molecule, human immunodeficiency virus (HIV), antiviral - Read more

Flagship-backed Sail Biomedicines cuts 12 jobs as part of organizational restructuring
RNA, GLP-1, obesity, autoimmune disease, cystic fibrosis, malaria, infectious disease - Read more

THE BAD
Politics & Policy

Trump announces 10% baseline tariff with higher rates for China, Japan, and EU, though pharmaceuticals appear exempt (for now)
Tariffs, drug pricing - Read more

THE UGLY
Lawsuits

Researchers sue NIH and HHS leaders over $1.1 billion in unlawfully canceled research grants, calling it wasteful and harmful to scientific progress
Federal research funding, National Institute of Health (NIH), US Department of Health & Human Services (HHS) - Read more

THE UGLY
Politics & Policy

Trump administration cuts Planned Parenthood's federal family planning funds, affecting healthcare services for low-income people
Planned parenthood, healthcare equity - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here